At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Anlotinib plus Sintilimabdrug
Likely dose
Anlotinib plus Sintilimab 12mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC): a Single Center, Single-arm Phase II Study (APICAL-CRC)
In Brief
A Phase 2 clinical trial evaluating Anlotinib plus Sintilimab for Colorectal Cancer and 5 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib and Sintilimab in advanced colorectal cancer as first-line treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Immunotherapy, Anlotinib, Sintilimab, Chemo-free Therapy, First-line Treatment
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartJun 2020
Primary CompletionSep 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedFeb 17, 2020
Enrollment StartJun 1, 2020
Primary CompletionSep 30, 2023
Study CompletionFeb 29, 2024
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.4 years ago
Interventions
Anlotinib plus Sintilimabdrug
Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w